Biomedical subjects
Ayse Mavi
Publications and source records attributed to Ayse Mavi.
Malignant lesions can mimic gastric uptake on FDG PET.
Gastric FDG uptake is a common observation on positron emission tomography (PET), which is most frequently caused by a nonmalignant etiology. However, a malignant lesion in the region of the stomach must not be overlooked. A 48-year-old woman with a history of melanoma in the esophagus and status postesophagectomy underwent FDG PET to evaluate for tumor recurrence. The images demonstrated hypermetabolism in the region of the location of the stomach. However, considering that the patient had a history of a stomach pullthrough procedure, we felt that this activity was nongastric and represented tumor recurrence, which was subsequently confirmed by computed tomography scan and histopathologic examination.
Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes.
UNLABELLED: This prospective study was designed to assess the utility of the dual time point imaging technique by (18)F-FDG PET in detecting primary breast cancer and to determine whether there is a relationship between (18)F-FDG uptake and its change over time and the histopathologic subtypes. METHODS: One hundred fifty-two patients with newly diagnosed breast cancer underwent 2 sequential PET scans (dual time point imaging) for preoperative staging. The maximum standardized uptake value (SUVmax) of (18)F-FDG was measured from both time points. The percent change in SUVmax (Delta%SUVmax) between time points 1 (SUVmax1) and 2 (SUVmax2) was calculated. Patients were divided into 2 groups according to histopathology as invasive and noninvasive. Invasive tumors were also divided into 2 groups (>10 mm and 4-10 mm). The tumor-to-contralateral normal breast (background) ratios of SUVmax at both time points for groups were measured and the Delta%SUVmax values were calculated. RESULTS: The mean +/- SD of the SUVmax1, the SUVmax2, and the Delta%SUVmax were 3.9 +/- 3.7, 4.3 +/- 4.0, and 8.3% +/- 11.5% for invasive; 2.0 +/- 0.6, 2.1 +/- 0.6, and 3.4% +/- 13.0% for noninvasive; and were 1.2 +/- 0.3, 1.1 +/- 0.2, and -10.0% +/- 10.8% for the contralateral normal breast groups, respectively. In the comparison of SUVmax1, Delta%SUVmax, and the tumor-to-background ratios among groups, all results were significant (P < 0.001). Visual assessment revealed that the sensitivity of dual time point imaging was 90.1% for invasive cancer >10 mm, 82.7% for invasive breast cancers 4-10 mm, and 76.9% for noninvasive breast cancers. CONCLUSION: Dual time point imaging is a simple and noninvasive method that may improve the sensitivity and accuracy of (18)F-FDG PET in assessing patients with primary breast cancer. The changes that are noted in SUVs in dual time point imaging vary depending on the histopathologic type of primary breast cancer.
Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer.
Fluorodeoxyglucose-PET imaging has secured an important role in the assessment and management of a multitude of pulmonary disorders, including solitary pulmonary nodules, lung cancer, and pleural diseases. While conventional imaging modalities such as chest radiography and CT are considered essential in these settings, FDG-PET can provide new information and complement structural imaging techniques in the evaluation of such disorders. In this review, the authors present a growing body of evidence that demonstrates and supports the utility of FDG-PET in the differentiation of benign and malignant pulmonary nodules, the assessment of lung cancer in various stages of disease, and the characterization of pleural diseases. In addition, new developments--such as prospects for potential utility of novel radiotracers and delayed imaging--that can further refine the role of FDG scans in the work-up of lung nodules and cancer and forecast the future place of PET in these common modalities are discussed.
PET in cardiology.
Myocardial perfusion imaging with single-photon emission CT (SPECT) is a key investigation in the work-up of patients with coronary artery disease. PET, however, with inherently better spatial and temporal resolution, offers several advantages over SPECT. The last decade has witnessed extensive application of PET techniques to assess myocardial viability and has provided valuable information important in analyzing the risk: benefit ratio for several therapeutic measures. Recent advances in PET instrumentation and radiopharmaceuticals have generated considerable interest to use PET for evaluating an array of cardiovascular disease.
PET in pediatric diseases.
FDG-PET is being increasingly applied to pediatric conditions, particularly in oncology. PET and PET/CT scanning in children are not currently supported by Centers for Medicare and Medicaid Services unless the disease condition coincides with a reimbursed adult condition. The recent merger of the Children's Cancer Group and the Pediatric Oncology Group to form the Children's Oncology Group creates an opportunity to examine the use of FDG-PET in the management of childhood tumors in multi-institutional, cooperative efforts. The interest in incorporating PET imaging technology in pediatric medicine has been evidenced by several recent review articles summarizing the ongoing progress in this area. Future data will show that FDG-PET provides useful diagnostic information and can play a pivotal role in the clinical management and care of children with disease.
Fluorodeoxyglucose-PET in the management of malignant melanoma.
FDG-PET is of limited use in patients with early-stage disease without nodal or distant metastases (stage I-II), because sentinel node biopsy is much more sensitive in detecting microscopic lymph node metastases. Because of the high tumor-to-background ratio, FDG-PET can highlight metastases at unusual sites that are easily missed with conventional imaging modalities. PET has been shown to have a strong role in detecting metastatic disease. FDG-PET is more sensitive than CT for detecting metastatic lesions in skin, lymph nodes, and abdomen, but CT is equivalent to or more sensitive than FDG-PET for detecting small pulmonary lesions. FDG-PET identifies the location and number of metastatic lesions in stage III and IV disease and therefore is important for surgical planning. Most of the false-negative FDG-PET results are caused by micrometastases and lesion smaller than 10 mm. Postsurgical inflammation, other inflammatory lesions, and some benign tumors cause some false-positive FDG-PET results.
Reflux esophagitis secondary to chemotherapy detected by serial FDG-PET.
Explore the source record for details and available documents.
FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature.
Primary adrenal lymphoma is an extremely rare entity. Only 70 cases have been reported in the English literature. Most of the patients are elderly men with bilateral adrenal masses without extraadrenal involvement. The most common presenting symptoms are fever, weight loss, lumbar pain, and/or symptoms of adrenal insufficiency. Of the cases reported, CT, ultrasound, and MRI were the imaging modalities used to describe the lesions. FDG PET has been used successfully to differentiate benign and malignant adrenal masses. The authors report a 67-year-old man diagnosed as having primary bilateral adrenal lymphoma and having no evidence of extraadrenal spread who was evaluated from the time of diagnosis to complete remission with FDG PET scanning. The literature of this unusual neoplasm is reviewed in detail.
Normal variants in [18F]-fluorodeoxyglucose PET imaging.
The number of fluorodeoxyglucose PET applications is increasing. In the process of reading fluorodeoxyglucose-PET scans, nuclear medicine physicians encounter a wide variety of normal findings, which must be recognized to determine the best management for patients. It is important to recognize and understand normal variants to avoid misinterpretation of more serious pathology. This article reviews different patterns of physiologic fluorodeoxyglucose uptake including changes with age.
PET: a revolution in medical imaging.
FDG-PET has had remarkable influence on the assessment of physiologic and pathologic states. The authors predict that FDG-PET imaging could soon become the most common procedure used by nuclear medicine laboratories and could remain so for an extended period of time. The power of molecular imaging lies in the vast potential for using biochemical and pharmacologic probes to extend applications arising from an understanding of cell biology to a large number of well-characterized pathologic states. Molecular imaging based upon tracer kinetics with positron-emitting radiopharmaceuticals could become the main source of information for the management of cancer patients. In that case, nuclear medicine procedures might become the most common imaging studies performed in the practice of medicine. This speculation is not farfetched when one realizes the enormous change that a single biologically important compound, FDG, has brought to the medical arena. The major challenge today is to attract the highly qualified individuals and to secure the resources needed to harness the opportunities in the specialty of molecular imaging.
FDG uptake in intercostal muscles is an indicator of severe respiratory disease.
Explore the source record for details and available documents.
Osteocutaneous flap prefabrication in rats.
Composite tissue defects may involve skin, mucosa, muscle, and bone together or in combinations of two or three of these tissues. Defects involving bone and skin are frequently encountered. Osteocutaneous flaps may be used to reconstruct these composite tissue defects. Sometimes, it is not possible to obtain a vascular osteocutaneous flap. Another way of producing an osteocutaneous flap that has the desired feature is prefabrication. Prefabrication of osteocutaneous flaps can be performed in two ways: (1) a vascularized osseous flap may be grafted with skin and (2) an osteocutaneous flap can be prefabricated by implanting an osseous graft into an axial island flap. There are many articles describing osteocutaneous flap prefabrication, but there is no comparison of both methods in the literature. As an experimental model for osteocutaneous flap prefabrication, rat tail bone was chosen. For the experiments, five groups were formed. Each group contained 10 rats. In the first experimental group, a vascularized osseous segment was skin grafted and an osteocutaneous flap was prefabricated. In the second experimental group, an osseous graft was implanted into an axial skin flap. To compare viability of skin and bone components of the two prefabrication groups, vascularized tail bone was elevated with overlying skin in the third group, a bone flap was elevated in the fourth group, and a skin flap that had been prefabricated by using vascular implantation was elevated in the fifth group. The authors examined five rats in each group by microangiography at the end of 4 weeks. On microangiographic analysis, all groups showed patency of vascular pedicles. There was no difference among the groups from the point of view of vascular patency and bone appearance. Bone scintigraphy was performed on the five rats in each group. On bone scintigraphic scans, the bone component of flaps was visualized in all groups except for group 5. The mean radioactivity value on the flap side was 10,362 +/- 541.1 in group 1, 10,241 +/- 1173 in group 2, 10,696 +/- 647.1 in group 3, and 10,696 +/- 647.1 in group 4. When the radioactivity values on the flap side were compared, no statistically significant difference among groups was seen, except for group 5 (p < 0.05). To evaluate bone metabolic activity, the bone component of flap and remaining last tail bone was harvested and the radioactivity of each specimen was measured with a well-type gamma counter. The parameter of percentage radioactivity in counts per minute per unit per gram of tissue was calculated. The value of the bone component of the flap side and the value of normal bone were estimated and results were compared. The mean result was 0.86 +/- 0.08 in group 1, 0.88 +/- 0.07 in group 2, 0.87 +/- 0.07 in group 3, and 0.81 +/- 0.04 in group 4. The difference among all groups was not statistically significant. Histologic examination was performed on all rats in each group and demonstrated that the bony component was viable, showing a cellular bone marrow, osteoblasts along bony trabeculae, and vascular channels in bone-containing groups. There were no significant microangiographic, histologic, or scintigraphic differences between the two experimental methods.
18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
UNLABELLED: (18)F-FDG PET is highly sensitive and specific for evaluation of the treatment response of nodal and extranodal diseases in patients with malignant lymphomas. However, no data are available in the literature with regard to (18)F-FDG PET for evaluation of the treatment response in patients with lymphomas with gastrointestinal tract (GIT) involvement. This study was undertaken to investigate the usefulness of (18)F-FDG PET in monitoring the response to the treatment of lymphomas in this setting. METHODS: We retrospectively analyzed 19 patients with different types of lymphomas (10 diffuse large B-cell lymphomas, 4 follicular lymphomas, 3 mantle cell lymphomas, and 2 Hodgkin's disease) involving GIT. Among 19 patients, 4 had gastric involvement, 13 had small bowel involvement, and 2 had small bowel plus colon involvement by lymphomas. All patients underwent (18)F-FDG PET before and after the completion of therapy. The results of (18)F-FDG PET were compared with the results of CT and clinical outcome; the presence of relapse was determined on the basis of positive biopsy results or clinical follow-up data. RESULTS: Of the 19 posttreatment PET scans, 13 showed no pathologic (18)F-FDG uptake, whereas 6 showed persistent (18)F-FDG uptake. Among the 13 patients who had negative PET scans, only 1 patient (7.7%) relapsed, whereas all 6 patients (100%) who had persistent abnormal (18)F-FDG uptake on posttherapy PET scans relapsed. Posttreatment CT scans were negative for 10 patients but showed persistent disease in the remaining 9 patients. Among the 10 patients who had negative CT scans, 9 remained in remission and 1 (10%) relapsed. Of the 9 patients who showed persistent disease, 6 (67%) relapsed and 3 (33%) remained in remission after the mean follow-up of 20 mo. The sensitivity, specificity, positive and negative predictive values, and accuracy of posttherapy (18)F-FDG PET were 86%, 100%, 100%, 92%, and 95%, respectively. The corresponding values for CT were 67%, 75%, 75%, 90%, and 79%, respectively. Patients with positive (18)F-FDG PET results had statistically significantly lower disease-free survival (DFS) (0%) than did those with positive CT results (33%) (P = 0.04). There was no statistically significant difference in DFS between patients with negative (18)F-FDG PET results and patients with negative CT results. CONCLUSION: A positive (18)F-FDG PET scan after the completion of chemotherapy in patients with lymphomas with GIT involvement is a strong predictor of relapse. (18)F-FDG PET has higher diagnostic accuracy than CT in the detection of residual disease after therapy. Despite the mild physiologic (18)F-FDG uptake in the GIT, (18)F-FDG PET has potential value in monitoring the response to treatment in patients with GIT lymphomas, particularly when pretreatment PET results are positive.
Intra-abdominal splenosis mimicking massive gastrointestinal bleeding.
Explore the source record for details and available documents.